Resources

Access expert content and insights, including whitepapers, case studies, presentations, and other valuable resources here.

GMP Manufacturing of Oncolytic Viruses: Critical Steps an…

The oncolytic virus (OV) sector needs to overcome several challenges to bring transformative cancer therapeutics to the clinic.   Not only …

What is the Secret to Oncolytic Virus Development?

There are few contract development and manufacturing organizations (CDMOs) capable of working with biopharmaceutical companies to develop adva…

Virus Particle Analysis by MADLS Technology

Over the past two decades, we have seen continued advancement of virus characterization and quantification technologies come to market due to …

Time to Outsource Viral Vector Development

A fast-growing sector The outsourcing of process development, manufacturing, and analytical testing in the viral product market has grown sig…

The Advantage of Engaging Your CDMO Early

One of the key things that I have learned from my many years in the biopharma market is that it is not only important to work with a trusted c…

Top Tips in Selecting your Viral Vector Partner

From cutting-edge therapies for deadly cancers, to developing effective vaccines, the viral vector space is an exciting place to be. However, …

Load more

Process Development

Full development services are offered to transfer and mature processes for optimized scale, productivity, product profile and cost of goods.

Analytical Development

Method development and transfer services span characterization and quality control assays for identity, purity, potency, titer, and safety.

QC Release & Stability Testing

In-house quality control and stability services ensure timely testing of bulk, in-process control, and final drug product.

Oncolytic Virus

Specialist in the manufacture of replication competent engineered and wild-type oncolytic viruses, with a deep track record you can trust.

Gene Therapy

Expertise across gene therapy vectors produced by transient, helper-virus, and stable producer cell lines minimize time-to-market.

Vaccines

Scalable capacity and effective cost of goods management for vaccine product development and manufacture.